Bydureon Bcise

Physical Activity, Type 2 Diabetes, Diet
Treatment
20 Active Studies for Bydureon Bcise

What is Bydureon Bcise

ExenatideThe Generic name of this drug
Treatment SummaryExenatide is a medication used to control blood sugar levels. It works by activating the GLP-1 receptor, which increases insulin secretion, lowers glucagon secretion, and slows digestion. Exenatide was approved by the FDA in 2005.
Byettais the brand name
image of different drug pills on a surface
Bydureon Bcise Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Byetta
Exenatide
2005
10

Effectiveness

How Bydureon Bcise Affects PatientsExenatide helps the body to better regulate its response to glucose. This means when glucose is present, insulin is released in the right amount and glucagon is released in a lower amount. During hypoglycemia, the normal amount of glucagon is still released. Additionally, exenatide slows down how quickly the stomach empties, leading to a slower and more controlled release of glucose into the body. These effects help to prevent both high and low blood sugar levels.
How Bydureon Bcise works in the bodyExenatide is a drug that helps control blood sugar levels. It does this by activating a certain receptor in the body, which then increases the production of insulin and decreases the production of glucagon. These hormones help regulate glucose levels in the body. Exenatide also slows down how quickly food leaves the stomach, which helps keep blood sugar levels steady. All of these effects work together to help prevent both high and low blood sugar.

When to interrupt dosage

The recommended quantity of Bydureon Bcise relies upon the diagnosed situation. The degree of dosage fluctuates, in light of the administration method delineated in the table below.
Condition
Dosage
Administration
Physical Activity
, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Subcutaneous, Solution, Solution - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Injection, suspension, extended release, Injection, suspension, extended release - Subcutaneous, Suspension, extended release, Suspension, extended release - Subcutaneous
Type 2 Diabetes
, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Subcutaneous, Solution, Solution - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Injection, suspension, extended release, Injection, suspension, extended release - Subcutaneous, Suspension, extended release, Suspension, extended release - Subcutaneous
Diet
, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Subcutaneous, Solution, Solution - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Injection, suspension, extended release, Injection, suspension, extended release - Subcutaneous, Suspension, extended release, Suspension, extended release - Subcutaneous

Warnings

Bydureon Bcise Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Exenatide may interact with Pulse Frequency
There are 20 known major drug interactions with Bydureon Bcise.
Common Bydureon Bcise Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Moderate
Exenatide can cause an increase in the absorption of (R)-warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.
(S)-Warfarin
Moderate
Exenatide can cause an increase in the absorption of (S)-Warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.
2,4-thiazolidinedione
Moderate
The risk or severity of hypoglycemia can be increased when Exenatide is combined with 2,4-thiazolidinedione.
4-hydroxycoumarin
Moderate
Exenatide can cause an increase in the absorption of 4-hydroxycoumarin resulting in an increased serum concentration and potentially a worsening of adverse effects.
AICA ribonucleotide
Moderate
The risk or severity of hypoglycemia can be increased when Exenatide is combined with AICA ribonucleotide.
Bydureon Bcise Toxicity & Overdose RiskAnimal studies have shown that exenatide use during pregnancy can cause deformities in the baby’s ribs and vertebrae and slow growth. Uncontrolled high blood sugar during pregnancy has been linked to a 25% risk of miscarriage. There are no known human studies on the effects of exenatide in pregnancy and it should only be prescribed if the benefits outweigh the risks. It is not known how exenatide affects breastfed infants or pediatric patients, so the risks and benefits should be weighed carefully. Older adults may be more likely to experience side effects due to their higher risk of renal impairment or other health issues,
image of a doctor in a lab doing drug, clinical research

Bydureon Bcise Novel Uses: Which Conditions Have a Clinical Trial Featuring Bydureon Bcise?

162 active trials are currently being conducted to assess the potential of Bydureon Bcise in providing relief for Type 2 Diabetes.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
164 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Bydureon Bcise Reviews: What are patients saying about Bydureon Bcise?

4.7Patient Review
1/22/2020
Bydureon Bcise for Type 2 Diabetes Mellitus
I've been using this product for six months now, and I'm really happy with it. The pens have been working great (no problems there), and the side effects weren't too bad once my body got used to the medication. Just be careful with what you eat; if you overdo it, you'll feel pretty sick. In just 90 days, my A1C went from 9.4 to 7.2, which is amazing!
4.3Patient Review
2/4/2019
Bydureon Bcise for Type 2 Diabetes Mellitus
After a few weeks of taking this medication, I really noticed an improvement in my condition. The injector is easy to use and painless, which is great. A common side effect that I experienced was bumps at the injection sight; however, they would go away after a couple of weeks and didn't cause any pain or discoloration.
3.3Patient Review
5/23/2019
Bydureon Bcise for Type 2 Diabetes Mellitus
I took this drug for three months and it worked great, A1C lowered to 6.6 and I found it easy to use. Once shaken, you could see it going in, so no problem with injection. the fourth month I developed severe gas and bloating, quickly followed by nausea, vomiting and diarhhea. A miserable three days!
3.3Patient Review
11/7/2018
Bydureon Bcise for Type 2 Diabetes Mellitus
The injector is not great. It can squirt out when you remove the cap and it can fail to penetrate the skin because of the shroud around the needle. If you can get it injected, it seems to work though.
3.3Patient Review
6/9/2022
Bydureon Bcise for Type 2 Diabetes Mellitus
The injector is faulty; two out of the last three times I've used it, the medication hasn't been injected and has instead sprayed out. This wastes an expensive pen each time, which costs me over $100 out of pocket.
2.3Patient Review
4/30/2019
Bydureon Bcise for Type 2 Diabetes Mellitus
I tried this for 8 weeks and saw no results.
1.7Patient Review
10/4/2021
Bydureon Bcise for Type 2 Diabetes Mellitus
The design of this product is very poor. I have wasted three needles trying to unscrew the cap after unlocking and mixing. As soon as I try to remove the cap, the needle springs out and ejects the contents.
1.7Patient Review
11/11/2018
Bydureon Bcise for Type 2 Diabetes Mellitus
The injector is terrible. It often squirts out when you remove the cap, and it can fail to penetrate the skin. I can't believe they released this before testing it properly.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bydureon bcise

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Bydureon BCise for?

"BYDUREON BCise is an injectable medicine that can help improve blood sugar levels in adults and children 10 years of age and older with type 2 diabetes mellitus. It should be used along with a healthy diet and exercise plan."

Answered by AI

Is Trulicity and Bydureon the same?

"Both Bydureon and Trulicity are in the same class of medication, meaning they work in the same way to improve blood sugar levels in people with type 2 diabetes."

Answered by AI

Is Bydureon considered insulin?

"No, Bydureon does not increase the amount of insulin in your body, but it does make your body release more insulin. Is Bydureon used for weight loss? No. Bydureon is not used for weight loss, even though weight loss is a common side effect."

Answered by AI

What is the difference between Bydureon pen and Bydureon BCise?

"Bydureon BCise is designed to be easy and convenient for patients to use. It only needs to be mixed for 15 seconds, compared to the Bydureon Pen which must be tapped 80 times or more to make sure the medicine is well mixed."

Answered by AI

Clinical Trials for Bydureon Bcise

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Bydureon Bcise clinical trials? We made a collection of clinical trials featuring Bydureon Bcise, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Bydureon Bcise clinical trials? We made a collection of clinical trials featuring Bydureon Bcise, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Have you considered Bydureon Bcise clinical trials? We made a collection of clinical trials featuring Bydureon Bcise, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security